LEO Pharma Enters into Rare Skin Diseases with US$760 M Deal with PellePharm

By Sharath Chandra Nakka & Michelle Liu

Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)

Published: 30 Nov-2018

DOI: 10.3833/pdr.v2018.i11.2375     ISSN: 1756-7874

Section: Research & Development



In the latest of its deals focusing on strengthening its dermatology portfolio, LEO Pharma has in-licensed PellePharm’s patidegib, an orphan drug currently under development for the prevention and treatment of Gorlin Syndrome, also known as nevoid basal cell carcinoma (BCC) syndrome...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details